• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » A New Buprenorphine Dosing Strategy for Easier Induction From Fentanyl

A New Buprenorphine Dosing Strategy for Easier Induction From Fentanyl

November 5, 2021
Oluwole Jegede, MD, PhD
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Oluwole Jegede, MD. Dr. Jegede has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Antoine D et al, Am J Addict 2021;30(1):83–87

The escalating rate of opioid overdose deaths has been linked to the rise of illicit fentanyl. Increasing evidence shows that fentanyl and its analogues, such as carfentanil and acetylfentanyl, are fast replacing heroin as the most commonly used illicit opioid for many people with opioid use disorder (OUD). Furthermore, fentanyl has become a common adulterant of many street drugs, meaning it is often used inadvertently with potentially lethal results.

The widespread availability of fentanyl has changed the landscape of opioid treatment, because its pharmacologic properties differ from other opioid agonists. In particular, fentanyl’s lipophilicity, rapid crossing of the blood-brain barrier, and sky-high receptor potency can make for tricky buprenorphine induction.

The usual method of buprenorphine induction consists of waiting for the patient to develop moderate withdrawal symptoms, then giving a 2–4 mg dose of sublingual buprenorphine and possibly repeating the dose after a few hours. This works well for most opioids; however, evidence indicates that patients are more likely to suffer precipitated withdrawal from this protocol if they have fentanyl in their system. In addition, “fentanyl” from the street can actually consist of a mixture of fentanyl, various fentanyl analogs, and other opioid agonists, further complicating the picture.

Realizing that precipitated withdrawal could deter people from seeking treatment, the authors set out to investigate whether frequent small doses of buprenorphine initiated at higher Clinical Opiate Withdrawal Scale (COWS) scores resulted in fewer precipitated withdrawal symptoms than the usual induction procedure.

Researchers recruited four participants who had recently used fentanyl but had been abstinent for 24 hours. Two patients underwent induction using the standard procedure: 4 mg of buprenorphine once COWS reached 9, followed by another dose three hours later. The other two patients underwent the novel induction strategy: 2 mg of buprenorphine at COWS of 13, followed by additional 2 mg doses at 1.5, 3.5, and six hours.

The researchers found that the patients who underwent the standard buprenorphine induction had severe precipitated withdrawal (defined as COWS > 12). One patient even had COWS above 30 shortly after receiving the first dose of buprenorphine. The patients who received the modified induction never scored above 10 once buprenorphine was initiated.

This study adds to growing evidence that lower initial doses of buprenorphine can ease the induction process. In a prior issue of CATR (November/December 2020), and in the research update on the previous page, we discussed microinduction, in which very low doses of buprenorphine are used to allow patients to start buprenorphine without having to go into withdrawal first. The dosing strategy being studied here is different, in that patients experience withdrawal prior to induction and the dose being utilized (2 mg) lies somewhere between microdosing (0.5 mg) and the standard induction protocol (4–8 mg).

CATR’S Take
This was only a small case series, but the strategy may be worth trying for your patients using fentanyl, especially if they have a history of precipitated withdrawal when initiating buprenorphine.
Addiction Treatment
KEYWORDS buprenorphine fentanyl induction medication-of-opioid-use-disorder-moud opioid-use-disorder
    Oluwole Jegede, MD, PhD

    Structural Brain Changes: How Imaging Affects Management of Late-Life Psychiatric Conditions

    More from this author
    www.thecarlatreport.com
    Issue Date: November 5, 2021
    SUBSCRIBE NOW
    Table Of Contents
    Buprenorphine Treatment
    Drug Overdoses in the US: Trends and Prevention Strategies
    Suicide Safety Planning for the Patient with Addiction
    A New Buprenorphine Dosing Strategy for Easier Induction From Fentanyl
    Buprenorphine Induction Without Withdrawal
    Suboxone vs. Vivitrol for Opioid Use Disorder: How Do you Choose?
    CME Post-Test - Opioid Epidemic Update, CATR, November/December 2021
    DOWNLOAD NOW
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.